These three pathways work in synergy to: Suppress hunger Burn stored fat Enhance insulin sensitivity Improve blood glucose levels Visual: Triple Agonist Biochemistry Pathway in Retatrutide Clinical Trial Highlights In a 2023 phase 2 trial, patients on Retatrutide experienced an average weight loss of 24.2% over 48 weeks. Compared to Semaglutide (Ozempic/Wegovy), Retatrutide showed superior fat mass reduction and appetite suppression . Also showed promise in improving HbA1c , insulin resistance, and non-alcoholic fatty liver disease (NAFLD)
These insights show whether your genetic profile predisposes you to stronger or weaker appetite suppression, which can inform whether you need earlier or later meal timing around your injection
Nooms ability to create lasting lifestyle changes along with metabolic health improvements has been shown in over 50 published peer-reviewed studies
Blood glucose levels were slightly but not significantly higher in the control group ( 2 (1) = 2.84, p = 0.09, f = 0.45
CLINICIAN-GUIDED METABOLIC SUPPORT Fort Myers,FL Clinician-guided GLP-1 microdosing Fort Myers,FL real conversations via video or phone
